肺动脉高压发病机制及治疗研究进展  

Progress of research on pathogenesis and treatment of pulmonary hypertension

作　　者：李涵飞 祝田田 赵繁荣[1] 陈宇静 LI Hanfei;ZHU Tiantian;ZHAO Fanrong;CHEN Yujing(School of Pharmacy,Xinxiang Medical University,Xinxiang 453003,Henan Province,China)

机构地区：[1]新乡医学院药学院,河南新乡453003

出　　处：《新乡医学院学报》2025年第5期426-431,共6页Journal of Xinxiang Medical University

基　　金：国家自然科学基金资助项目(编号:82300073);河南省高等学校重点科研项目计划(编号:22A180010);新乡医学院人才(博士)支持计划项目(编号:XYBSKYZZ202108)。

摘　　要：肺动脉高压(PH)是一种严重的心肺功能障碍性疾病,以进行性血管重构为特征,治疗不当会导致右心功能衰竭甚至死亡。近年来,随着对PH发病机制的深入研究,针对不同信号通路的靶向药物不断涌现,为PH患者带来了新的希望。本文就PH的发病机制、靶向治疗药物、面临的挑战及未来发展方向等方面进行综述,重点阐述当前临床实践中广泛应用的PH靶向治疗药物如前列环素类制剂、内皮素受体拮抗剂以及5型磷酸二酯酶抑制剂等的作用机制、临床应用及最新研究进展,并探讨个体化治疗、药物联合治疗、新型药物研发等PH治疗领域面临的挑战,以期为PH的新型治疗药物的开发提供参考。Pulmonary hypertension(PH)is a serious cardiopulmonary dysfunction disease characterized by progressive vascular remodeling,and improper treatment can lead to right heart failure or even death.In recent years,with the in-depth study of the pathogenesis of PH,targeted drugs against different signaling pathways have been developed,bringing new hope to PH patients.In this article,the pathogenesis of PH,targeted therapeutic agents,challenges and future development directions were reviewed.It focuses on the mechanism of action,clinical application,and recent advances in research of widely used targeted therapeutic agents for PH,such as prostacyclin analogs,endothelin receptor antagonist,and phosphodiesterase type 5 inhibitor.In addition,the challenges in the field of PH treatment,such as individualized treatment,drug combination therapy,novel drug development,were also discussed,so as to provide a reference for the clinical diagnosis and treatment of PH.

关 键 词：肺动脉高压 血管重构 发病机制 靶向药物 

分 类 号：R543.2[医药卫生—心血管疾病]